Inpharma 1378 - 15 Mar 2003
MPI 5010: antitumour activity inmalignant melanoma
Intratumoural MPI 5010* is associated withantitumour activity in patients with refractory orrecurrent melanoma and cutaneous or soft tissuemetastases, report researchers from the US andGermany.
Their open-label study involved 28 such patients whoreceived intralesional injections of MPI 5010 as a gelvolume of 0.5mL containing 2mg of cisplatin plus0.05mg of epinephrine [adrenaline].** Up to six weeklyinjections were administered within an 8-week period oruntil complete response was achieved. Patients couldreceive additional courses if treated tumours recurred orregressed, or if new tumours developed during follow-up. Each tumour could be treated with a single injectionor multiple injections depending on the lesionconformation. Twenty-five patients with 244 lesionswere evaluable for efficacy.
The objective response rate for all treated tumours(1–72 per patient) was 53% (consisting of completeresponses in 114 tumours and partial responses in 16tumours), while the response rate for the target tumours(i.e each patient’s single, most symptomatic, largest ormost threatening tumour) was 44%. Median responsedurations were 347 days and 63 days, respectively. Themedian number of treatments per tumour was five.
MPI 5010 was associated with significant local toxicitybut little systemic toxicity. The most common severelocal effects were necrosis (61% of patients), erythema(46%), ulceration (43%), eschar (43%) and swelling(36%).* Chiron Corporation; preregistration in Europe and the US for headand neck cancer** The study was supported by Matrix Pharmaceutical, Inc., withwhich one of the researchers was affiliated.
Oratz R, et al. Intratumoral cisplatin/adrenaline injectable gel for the treatment ofpatients with cutaneous and soft tissue metastases of malignant melanoma.Melanoma Research 13: 59-66, Feb 2003 800933521
1
Inpharma 15 Mar 2003 No. 13781173-8324/10/1378-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
